HanWinTunMD

PubMed

• 1 citations
  Incidence of Central Nervous System Relapse in Primary Mediastinal Large B-Cell Lymphoma: Implications for Central Nervous System Prophylaxis.
  Izel Okcu, Yucai Wang, Allison M Bock, Jihao Zhou, Muhamad Alhaj Moustafa
  Clinical Lymphoma, Myeloma & Leukemia. 2025-02-01
• Targets and treatments in primary CNS lymphoma.
  Christina von Roemeling, Andrés J M Ferreri, Carole Soussain, Han W Tun, Christian Grommes
  Leukemia & Lymphoma. 2024-08-01
• Clinical and Genomic Profile of Primary Cranial Neurolymphomatosis.
  Emily B Wolf, Robin Imperial, Liuyan Jiang, Amit K Agarwal, Han W Tun
  Journal of Blood Medicine. 2024-01-01

Journal Articles

• Phase I Study of Pomalidomide and Dexamethasone for relapsed/refractory Primary CNS or Vitreo-Retinal Lymphoma  
  Lisa M DeAngelis, Han W Tun, David Schiff, Kurt A Jaeckle, Christian Grommes, Patrick B Johnston, Craig B Reeder, Thomas E Witzig, Blood

Abstracts/Posters

• Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience
  Han W. Tun, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalid...
  Han W. Tun, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relap...
  Han W. Tun, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience
  Han W. Tun, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/8/2019
• Join now to see all